Skip to contentG
GeneDx Holdings Corp.
G
WGSGeneDx Holdings Corp. Q1 2023 · 10-Q
Revenue$43.14M$43.14M−20.0% vs Q1 2022 Net Income-$60.99M-$60.99MN/M vs Q1 2022 EPS Diluted-$3.04-$3.04N/M vs Q1 2022 Gross Profit$15,236,000+170.9% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
GeneDx Holdings Corp. · CIK 1818331 · Engraved from SEC EDGAR
Operating Cash Flow-$55,560,000N/M Free Cash Flowderived-$55,560,000N/M Margins · derivedGross margin35.3%+24.9 pt vs Q1 2022
Operating margin-139.9%+25.6 pt vs Q1 2022
Net margin-141.4%+1.2 pt vs Q1 2022
ended Mar 31, 2023 · filed May 9, 2023 · 39 d after period end